Treatment of psychosis in elderly people
暂无分享,去创建一个
[1] D. Jeste,et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.
[2] J. Cohen-Mansfield. Nonpharmacologic Interventions for Psychotic Symptoms in Dementia , 2003, Journal of geriatric psychiatry and neurology.
[3] D. Jeste,et al. Management of late-life psychosis. , 1996, The Journal of clinical psychiatry.
[4] R. Scollay. Directions For Research And Policy , 2005 .
[5] S. Lovestone,et al. Do neuroleptic drugs hasten cognitive decline in dementia? , 1997, BMJ.
[6] E. Perry,et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.
[7] S H Ferris,et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.
[8] C. Altar,et al. Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile , 2004, Journal of psychopharmacology.
[9] R. Howard,et al. Donepezil for the treatment of psychosis in dementia with Lewy bodies , 2000, International journal of geriatric psychiatry.
[10] S. Bartels,et al. Enhanced Skills Training and Health Care Management for Older Persons with Severe Mental Illness , 2004, Community Mental Health Journal.
[11] L. Schneider,et al. Meta-Analysis of Controlled Pharmacologic Trials , 1997, International Psychogeriatrics.
[12] D. Jeste,et al. Understanding and Managing Psychosis in Late Life , 2003 .
[13] H. Brodaty,et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. , 2003, The Journal of clinical psychiatry.
[14] M F Weiner,et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. , 1995, The American journal of psychiatry.
[15] John E. Cooper,et al. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.
[16] J. Lieberman,et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. , 1998, The American journal of psychiatry.
[17] S. Targum,et al. Psychoses in the elderly: a spectrum of disorders. , 1999, The Journal of clinical psychiatry.
[18] T. Macewan,et al. CSM warning on atypical psychotics and stroke may be detrimental for dementia , 2004, BMJ : British Medical Journal.
[19] G. Small,et al. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease , 1999, Biological Psychiatry.
[20] V. Lerner,et al. Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease , 2002, Clinical neuropharmacology.
[21] A. Morreale,et al. Drug-induced psychosis and depression in the elderly. , 1988, The Psychiatric clinics of North America.
[22] R. Lévy,et al. Which factors affect treatment response in late paraphrenia? , 1992 .
[23] A. Burns,et al. The Biology of Psychosis in Older People , 2003, Journal of geriatric psychiatry and neurology.
[24] S. Kuzuhara. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma , 2001, Journal of Neurology.
[25] D. Jeste,et al. Schizophrenia in late life: findings challenge traditional concepts. , 2001, Harvard review of psychiatry.
[26] G. Grossberg,et al. The treatment of psychosis in late life. , 1998, The Journal of clinical psychiatry.
[27] Murat Emre,et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.
[28] I. Skoog,et al. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. , 2002, Archives of general psychiatry.
[29] S. Zarit,et al. Subjective burden of husbands and wives as caregivers: a longitudinal study. , 1986, The Gerontologist.
[30] J. Cummings,et al. Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies , 2002, Dementia and Geriatric Cognitive Disorders.
[31] Abraham Weizman,et al. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. , 1999, Comprehensive psychiatry.
[32] J. Frost. Paraphrenia and paranoid schizophrenia. , 1969, Psychiatria clinica.
[33] I. McKeith,et al. Olanzapine in dementia with Lewy bodies: a clinical study , 1999, International journal of geriatric psychiatry.
[34] D. Weintraub,et al. Pharmacologic Management of Psychosis in the Elderly: A Critical Review , 2003, Journal of geriatric psychiatry and neurology.
[35] F. Post. Persistent Persecutory States of the Elderly , 1968 .
[36] W. L. Ooi,et al. Evaluation of Simulated Presence: A Personalized Approach to Enhance Well‐Being in Persons with Alzheimer's Disease , 1999, Journal of the American Geriatrics Society.
[37] C. d’Souza,et al. MANAGEMENT OF PSYCHOSIS IN PARKINSON'S DISEASE , 2003, International journal of clinical practice.
[38] R. Tamura,et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.
[39] J. Morris,et al. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .
[40] J. Friedman,et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.
[41] R. Levy,et al. Neuropathological Correlates of Psychotic Phenomena in Confirmed Alzheimer's Disease , 1994, British Journal of Psychiatry.
[42] G. Lenzi,et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease , 2002, Neurological Sciences.
[43] C. Lyketsos,et al. Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates , 2000, International journal of geriatric psychiatry.
[44] G. Dunn,et al. Cognitive behavioural therapy for drug-resistant psychosis. , 1994, The British journal of medical psychology.
[45] K. Kosaka,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.
[46] D. Jeste. Tardive dyskinesia rates with atypical antipsychotics in older adults. , 2004, The Journal of clinical psychiatry.
[47] L. Schneider,et al. Quetiapine for Elderly Patients With Psychotic Disorders , 2000 .
[48] J. Byrne,et al. What Is Lewy Body Dementia? , 2020, A Caregiver’s Guide to Lewy Body Dementia.
[49] D. Jeste,et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. , 2001, The American journal of psychiatry.
[50] M. Fuller,et al. Pharmacokinetics of Quetiapine in Elderly Patients with Selected Psychotic Disorders , 2004, Clinical pharmacokinetics.
[51] G. Grossberg,et al. Treatment of Late‐onset Psychotic Disorders , 2002 .
[52] H. Sackeim,et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.
[53] B. Stotsky,et al. HALOPERIDOL VERSUS THIORIDAZINE FOR HOSPITALIZED PSYCHOGERIATRIC PATIENTS: DOUBLE‐BLIND STUDY * , 1971, Journal of the American Geriatrics Society.
[54] Jeffrey L. Cummings,et al. Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.
[55] J. Cummings,et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. , 1999, Archives of neurology.
[56] Mrc Psych,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .
[57] I. Katz,et al. Schizophrenia and older adults. An overview: directions for research and policy. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[58] J. Jankovic,et al. Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.
[59] J. O'Brien,et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments , 2001, International journal of geriatric psychiatry.
[60] R. Liberman. Psychosocial treatments for schizophrenia. , 1994, Psychiatry.
[61] E. Wolters,et al. Intrinsic and extrinsic psychosis in Parkinson's disease , 2001, Journal of Neurology.
[62] D. Jeste,et al. Late‐life Psychotic Disorders: Nosology and Classification , 2002 .
[63] S. Madhusoodanan,et al. Experience with the Atypical Antipsychotics—Risperidone and Olanzapine in the Elderly , 1999, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[64] D. Jeste,et al. Late-Onset Schizophrenia and Very-Late-Onset Schizophrenia-Like Psychosis: An International Consensus , 2000 .
[65] Principles of Pharmacology , 2003 .
[66] A. Burns,et al. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease , 2004, Expert review of neurotherapeutics.
[67] S. Targum. Treating Psychotic Symptoms in Elderly Patients. , 2001, Primary care companion to the Journal of clinical psychiatry.
[68] C. Fairburn,et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up , 1997, BMJ.
[69] D. Jeste,et al. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[70] Nir Giladi,et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease , 2000, Journal of Neural Transmission.
[71] S. Finkel. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. , 2004, Clinical therapeutics.
[72] C. Camp,et al. Prospective memory intervention in Alzheimer's disease. , 1992, Journal of gerontology.
[73] B. Lawlor,et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.
[74] W. S. Clark,et al. Long‐term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia , 2001, International journal of geriatric psychiatry.
[75] A. Burns,et al. Neuroleptic sensitivity in dementia with cortical Lewy bodies. , 1992, BMJ.
[76] M. Roth,et al. Environmental and hereditary factors in the schizophrenias of age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. , 1961, The Journal of mental science.
[77] L. Tune,et al. Schizophrenia in late life. , 2003, The Psychiatric clinics of North America.
[78] J. Hare,et al. Video RespiteM for cognitively impaired persons In nursing homes , 1997 .
[79] S. Madhusoodanan,et al. Clinical Experience with Aripiprazole Treatment in Ten Elderly Patients with Schizophrenia or Schizoaffective Disorder: Retrospective Case Studies , 2004, CNS Spectrums.
[80] J. Mintzer,et al. Psychosis in Elderly Patients: Classification and Pharmacotherapy , 2003, Journal of geriatric psychiatry and neurology.
[81] G A Chase,et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.
[82] L. Beckett,et al. Psychotic Symptoms and Physically Aggressive Behavior in Alzheimer's Disease , 1997, Journal of the American Geriatrics Society.
[83] E. Granholm,et al. Development of an integrated cognitive-behavioral and social skills training intervention for older patients with schizophrenia. , 2000, The Journal of psychotherapy practice and research.
[84] D. Q. Mcmanus,et al. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. , 1999, The Journal of clinical psychiatry.
[85] R. Bullock,et al. Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series , 2002, Current medical research and opinion.
[86] I. Ferrier,et al. An evaluation of the predictive validity and inter‐rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type , 1994, Neurology.
[87] P. Tariot,et al. Long-Term use of quetiapine in elderly patients with psychotic disorders. , 2000, Clinical therapeutics.
[88] M. Sajatovic,et al. Olanzapine therapy in elderly patients with schizophrenia. , 1999, Psychopharmacology bulletin.
[89] M. Albert,et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.
[90] N. Herrmann,et al. Atypical antipsychotics and risk of cerebrovascular accidents. , 2004, The American journal of psychiatry.